Iqvia Holdings (IQV) Long-Term Deferred Tax (2011 - 2026)
Iqvia Holdings' (IQV) quarterly Long-Term Deferred Tax came in at $421.0 million in Q2 2026, up 22.03% year-over-year from $345.0 million in Q2 2025, and up 17.6% quarter-over-quarter from $358.0 million in Q1 2026.
Analysis
Iqvia Holdings (IQV) Long-Term Deferred Tax (2011 - 2026) Analysis & Trends
Iqvia Holdings has disclosed Long-Term Deferred Tax across 16 years of filings, most recently posting $421.0 million for Q2 2026.
- In Q2 2026, Long-Term Deferred Tax rose 22.03% year-over-year to $421.0 million; the TTM figure through Jun 2026 stood at $421.0 million (up 22.03% YoY), while the FY2025 annual figure was $357.0 million, up 84.02% from the prior year.
- Long-Term Deferred Tax came in at $421.0 million for Q2 2026 at Iqvia Holdings, up from $358.0 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $421.0 million in Q2 2026 to a low of $97.0 million in Q3 2022.
- Average Long-Term Deferred Tax over 5 years is $208.7 million, with a median of $161.0 million recorded in 2024.
- Year-over-year, Long-Term Deferred Tax declined 7.62% in 2022 and surged 137.8% in 2025.
- Over 5 years, Long-Term Deferred Tax stood at $118.0 million in 2022, then jumped by 40.68% to $166.0 million in 2023, then climbed by 16.87% to $194.0 million in 2024, then surged by 84.02% to $357.0 million in 2025, then rose by 17.93% to $421.0 million in 2026.
- Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $421.0 million in Q2 2026, $358.0 million in Q1 2026, and $357.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 421.00 Mn |
| Mar 31, 2026 | 358.00 Mn |
| Dec 31, 2025 | 357.00 Mn |
| Sep 30, 2025 | 390.00 Mn |
| Jun 30, 2025 | 345.00 Mn |
| Mar 31, 2025 | 245.00 Mn |
| Dec 31, 2024 | 194.00 Mn |
| Sep 30, 2024 | 164.00 Mn |
| Jun 30, 2024 | 158.00 Mn |
| Mar 31, 2024 | 152.00 Mn |
| Dec 31, 2023 | 166.00 Mn |
| Sep 30, 2023 | 111.00 Mn |
| Jun 30, 2023 | 115.00 Mn |
| Mar 31, 2023 | 125.00 Mn |
| Dec 31, 2022 | 118.00 Mn |
| Sep 30, 2022 | 97.00 Mn |
| Jun 30, 2022 | 120.00 Mn |
| Mar 31, 2022 | 120.00 Mn |
| Dec 31, 2021 | 124.00 Mn |
| Sep 30, 2021 | 105.00 Mn |